Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 341-360 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 341 | NeevCloud lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable because no direct positive evidence survived the 90-day recent evidence window in the retained reviewed sources. Why now: Why now is weak: despite membership rationale referring to partnerships and orbital data center / AI inferencing context, the retained reviewed sources contain zero evidence after recent evidence window and no citable article summaries. Caveats: Phase-2 membership rationale references, and: but no summaries or direct evidence are retained here for factual claims. The reviewed sources itself says NeevCloud is space-adjacent and not clearly a qualifying space company. |
| 342 | Neo Space Group lowweak | Opp 1 Risk 2 | Thesis: Potential opportunity exists if Neo Space Group is a meaningful customer or distribution node for satellite imagery supply to the Saudi government, but the reviewed sources does not provide available direct evidence within the recent evidence window to assess durability or monetization. Why now: No validated near-term or durable timing signal is available in the available evidence. Recency is uncertain because zero after-recent evidence window evidence were available. Caveats: Phase-2 rationale references, but no or summary is provided in the reviewed sources. Counterparty context should not be treated as propagated evidence for Neo Space Group's own thesis. Coverage debug shows zero evidence after recent evidence window. |
| 343 | NewOrbit lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence rationale says NewOrbit raised a £13.8 million Series A and is building VLEO sovereign communications satellites, but no retained evidence are present here to support a stronger ranked opportunity. Why now: No retained post-recent evidence window evidence are available, so current timing cannot be established from these reviewed sources. Caveats: Only membership rationale supports the company in this screen. No citeable retained evidence after recent evidence window. |
| 344 | OHB SE lowweak | Opp 1 Risk 1 | Thesis: No within the recent evidence window direct positive evidence was available, so there is insufficient reviewed sources support to form a positive 1 year+ opportunity thesis. Why now: There is no retained article or evidence row after the 90-day recent evidence window for OHB SE; recency-based ranking is therefore not supported by the reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 cohort membership rationale is not directional evidence and cannot substitute for retained article evidence. Because no article were retained after recent evidence window, no company-specific factual thesis can be cited from these reviewed sources. |
| 345 | Optimized Electrotech Pvt Ltd lowweak | Opp 1 Risk 1 | Thesis: The membership rationale suggests funding and expansion into space-based sensing with initial satellite platform orders, but the reviewed sources provide no retained within the recent evidence window article evidence or to support a positive thesis. Why now: No retained company evidence after the 90-day recent evidence window means there is no evidence-set-backed timing reason to rank this name higher now. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs, and, but no or retained evidence text are available here. Without retained article evidence, absence of bad news is not positive evidence. |
| 346 | Orbex mediumweak | Opp 1 Risk 5 | Thesis: Orbex has only minimal current opportunity evidence in these reviewed sources because the cited article context about its Prime microlauncher predates the 90-day recent evidence window and therefore should not be relied on as current support. Why now: The only surfaced article is dated February 17, 2026, outside the reviewed sources cutoff date of March 29, 2026, and the evidence recent evidence review says both rows were dropped; the article summary said Orbex released new photographs of its microlauncher Prime 'as the company looks to secure a future'. Because this is outside recent evidence window, recency support is absent. Evidence
Caveats: Primary surfaced evidence is outside recent evidence window and should not be treated as current proof. No in-recent evidence window direct positive or negative evidence is available. |
| 347 | OrbitOn lowweak | Opp 1 Risk 1 | Thesis: OrbitOn appears in an external SpaceFund satellite-servicing listing as 'Developing an on-orbit satellite servicing solution,' which is relevant product context, but the article is dated March 4, 2025 and was dropped by the 90-day recent evidence window, so it cannot support a current scored opportunity thesis in these reviewed sources Why now: Why now is weak because the only visible article has March 4, 2025 on a source date basis and the reviewed sources report no current evidence was retained after the March 29, 2026 cutoff Evidence
Caveats: Only article detail shown is outside the 90-day recent evidence window and was dropped. Database/listing style evidence is weaker than company-specific event evidence. External supporting source context is relevance context, not stronger than direct retained evidence. |
| 348 | Palantir Technologies lowweak | Opp 1 Risk 2 | Thesis: This reviewed sources does not provide citable reviewed evidence to support an opportunity thesis for Palantir despite a membership rationale mentioning possible participation in a U.S. Space Force Golden Dome context. Why now: Why now is weak because the reviewed sources references article IDs, and in the membership rationale, but no or reviewed evidence are provided for ranking use. Caveats: High mention count is not conviction. Cohort relevance via Space Force context is not enough without direct event/fact evidence. Coverage debug shows zero evidence after recent evidence window despite large article universe. |
| 349 | Paras Defence and Space Technologies Ltd lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supported within the reviewed sources' 90-day evidence window. The only cited reviewed sources rationale is older context that the company incorporated a semiconductor subsidiary, but no within the recent evidence window direct positive evidence is available in these reviewed sources. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Paras Defence and Space Technologies Ltd. Caveats: Phase-2 membership rationale references article, but the reviewed sources does not provide or quoted evidence for that item, so it cannot be used as a factual directional citation. No direct positive or negative evidence survived the 90-day recent evidence window. |
| 350 | Parsons Corporation lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only provides older membership context that Parsons has 'space' among technology areas and appears in an SSA market report, but no within the recent evidence window direct positive evidence is available, so no positive thesis is supportable here. Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Parsons Corporation. Caveats: Phase-2 membership rationale references articles: and, but the reviewed sources provide no for citation. Article-level market-report inclusion is weaker than direct company-specific operating evidence. |
| 351 | PhysicsX lowweak | Opp 1 Risk 1 | Thesis: Phase-2 rationale says PhysicsX raised $300M, but the reviewed sources characterizes the source as a broad tech funding roundup and provides no retained direct positive evidence inside the 90-day window, so the opportunity case is not currently evidenced. Why now: There is no current catalyst evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0. Caveats: Funding-round context in rationale lacks -cited retained evidence here. Space relevance is explicitly weak in the reviewed sources rationale. |
| 352 | PierSight lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, despite membership rationale describing PierSight as building the Varuna 2.0 SAR and AIS maritime-monitoring satellite. Why now: Why now is unsupported because the reviewed sources show no surviving evidence after recent evidence filtering; there is no direct dated milestone or problem signal to anchor a 1 year+ thesis. Caveats: Only membership-level rationale is present; no citable evidence survived. No direct company-specific positive or negative events are available in the reviewed sources. Low scores reflect evidence scarcity. |
| 353 | Pixxel lowweak | Opp 1 Risk 1 | Thesis: The earlier Pixxel reviewed sources version suggests Earth-observation and fundraising relevance in membership rationale, but there are no retained within the recent evidence window evidence or article summaries to support a current opportunity thesis. Why now: Why now is weak because no articles or evidence were retained after the March 29, 2026 cutoff in these reviewed sources version. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without, which cannot be cited as factual support here. |
| 354 | Portal Space Systems lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources' rationale mentions a $50 million Series A and maneuverable spacecraft technology, but no retained within the recent evidence window article evidence is present here to substantiate a positive thesis. Why now: There is no retained evidence inside the 90-day recent evidence window, so no current catalyst or business-state update is citable from these reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale references article IDs, and, but no or retained summaries are supplied. Low score reflects lack of citable evidence, not a negative business judgment. |
| 355 | Precursor SPC lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from retained evidence. The phase-2 rationale says Precursor SPC uses Spire data for hypersonic tracking and an AI/ML ionospheric nowcasting system tied to article, but the reviewed sources provide no representative article details, quote, or and no retained evidence after recent evidence window. Why now: Why now is weak because the reviewed sources show no available post-recent evidence window evidence; evidence recent evidence review kept_rows is 0 and coverage data articles after recent evidence window is 0. Caveats: Phase-2 rationale references without or retained evidence detail, so it is not sufficient for factual grounding here. No direct positive or negative evidence arrays are populated. Low scores are an evidence-gap judgment, not a business conclusion. |
| 356 | Quantum Opus lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources references older membership support that Quantum Opus helped build a lunar-Earth laser communication terminal used on Artemis II via article, but there is no retained in-window direct positive evidence with to support a current opportunity thesis. Why now: There is no clear why-now catalyst because coverage after the 90-day recent evidence window is empty. Caveats: Membership support exists but no representative article is provided for. No retained evidence after recent evidence window. No direct business-state update, financing, contract, or customer traction evidence is available. |
| 357 | Quantum Systems GmbH lowweak | Opp 1 Risk 1 | Thesis: No direct positive evidence is available. The reviewed sources say Quantum Systems is mentioned only via founders investing in another startup and as a portfolio-company reference, which is not sufficient for a positive company thesis. Why now: There is no supported near-term or long-horizon catalyst in the reviewed sources because zero post-recent evidence window evidence were available. Caveats: Phase2 rationale references article IDs: and: as article context only, but no were provided in the reviewed sources. Coverage data shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Context-only mentions and portfolio references cannot substitute for direct positive or negative evidence. |
| 358 | Relativity Space lowweak | Opp 1 Risk 2 | Thesis: Relativity Space has a plausible long-horizon opportunity narrative as a rocket developer with financing context in membership rationale, but the reviewed sources contain no retained evidence within the recent evidence window to support a current opportunity call. Why now: Why now is weak because there are no retained post-cutoff article summaries or evidence in the reviewed sources. Caveats: No retained evidence after recent evidence window. The modest risk uplift reflects uncertainty from lack of current confirmation, not a direct adverse event. |
| 359 | Rocket Factory Augsburg lowweak | Opp 1 Risk 2 | Thesis: The membership rationale mentions focus on a first test launch later in the summer, which could be strategically important, but there is no retained evidence row to support a scored positive thesis. Why now: No retained article or event evidence remains after recent evidence filtering; the only hint is a membership rationale referencing first test-launch focus via article: without an included summary. Caveats: Cannot treat membership rationale alone as strong directional proof. No article summary or retained evidence row is included for article |
| 360 | Rogers Communications Inc. lowweak | Opp 1 Risk 1 | Thesis: Only a very weak opportunity read is possible: the reviewed sources rationale says Rogers was mentioned as a Starlink telco partner in a SpaceX IPO article, implying possible exposure to direct-to-device or satellite connectivity, but no in-recent evidence window company evidence or citable article summary were available for Rogers in these reviewed sources. Why now: There is no available 90-day evidence for Rogers in these reviewed sources; coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window, so there is no supported 'why now' catalyst in the provided evidence. Caveats: No direct positive or negative evidence were available after the 90-day recent evidence window for Rogers. Phase2 rationale references support references including: but no article or article summary for that item is included in these reviewed sources, so it cannot be cited as factual evidence. Opportunity score is kept near zero because the evidence standard require positive evidence, not mere absence of risk. |
Risk view
Showing rows 141-160 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 141 | Cosmoserve Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mainly early-stage execution uncertainty and limited evidence depth: only two articles considered and zero available evidence after recent evidence window. Why now: Why now is weak because the reviewed sources does not establish current demo timing or funding status with direct evidence after recent evidence window. Caveats: Private company with thin visible evidence in these reviewed sources. Mission/demo status cannot be validated from available evidence. |
| 142 | D-Orbit lowweak | Opp 3 Risk 2 | Thesis: The main risk is evidentiary: the reviewed sources lack strong recent company-specific event/facts within the recent evidence window, limiting confidence on current execution state. Why now: Why-now is weak because retained evidence after recent evidence window is mostly undated context; one cited article is from February 14, 2026 and therefore outside the 90-day evidence window, while the remaining available context is undated. Evidence
Caveats: Reviewed evidence membership rationale mentions a €119 million ESA contract, but no citeable retained row for that contract is included here. Series D funding mention is in a February 14, 2026 article outside the 90-day recent evidence window. Undated context is not recency proof. |
| 143 | Dhruva Space lowweak | Opp 4 Risk 2 | Thesis: The risk is that none of the cited grant or partnership evidence is actually available into the kept post-recent evidence window evidence set, so durability, funding size, execution status, and commercial conversion remain unverified in the reviewed sources. Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited. Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated. |
| 144 | EarthDaily lowweak | Opp 1 Risk 2 | Thesis: Main risk in these reviewed sources is evidence absence rather than a documented business setback. With no available within the recent evidence window direct positive or negative evidence, visibility into current traction, financing, or execution is poor. Why now: Why now is weak because the reviewed sources show zero evidence kept within the 90-day recent evidence window for ranking, making recency and business-state assessment uncertain. Caveats: Phase-2 membership rationale references: but no or available evidence row is provided in these reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Cannot treat cohort membership as thesis attractiveness. |
| 145 | ElevationSpace mediummedium | Opp 6 Risk 2 | Thesis: Risk is mostly normal scale-up and execution risk from pursuing ambitious transportation and recovery-platform goals; the reviewed sources does not provide direct negative evidence such as delays, litigation, or financing stress. Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon. Evidence
Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration. |
| 146 | Eta Space lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources does not provide material negative evidence, but development and mission-execution risk remain implicit because the thesis rests on a demonstration mission rather than proven commercial scale. Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields. Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction. |
| 147 | Exquadrum, Inc. lowweak | Opp 2 Risk 2 | Thesis: The evidence is minimal and mostly acquisition context rather than direct company-specific operating evidence. Without retained post-recent evidence window detail, there is no basis for a stronger opportunity or risk call, and ownership/status changes may have already altered standalone operating exposure. Why now: No retained evidence establishes current milestone timing or post-acquisition integration progress, so there is no strong why-now supported in these reviewed sources. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Acquisition context is weaker than direct operating evidence. |
| 148 | Fergani Space lowweak | Opp 2 Risk 2 | Thesis: The main risk is evidentiary uncertainty: there is no available direct adverse evidence, but there is also no post-recent evidence window operating, financing, customer, or execution evidence to confirm momentum. Why now: There is no credible 'why now' catalyst in the reviewed sources because articles after recent evidence window and evidence after recent evidence window are both zero for this company. The only cited support is older or excluded from the active evidence set: article, referenced in the membership rationale, was outside the kept recent evidence window according to the company coverage report. Caveats: No evidence were available after recent evidence filtering. No representative articles or additional_company_articles were provided. Membership rationale is weaker than direct event/fact evidence. |
| 149 | Firefly Aerospace lowweak | Opp 4 Risk 2 | Thesis: The evidence is limited to one recent article-level source and does not provide strong company-specific downside evidence, so risk stays low but uncertainty remains high. Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later. Evidence
Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window. |
| 150 | GalaxEye Space lowweak | Opp 2 Risk 2 | Thesis: Risk is mainly lack of current evidentiary confirmation rather than documented business trouble. Why now: There is no within the recent evidence window evidence available in these reviewed sources for GalaxEye Space; timing and maturity of current milestones cannot be confirmed from reviewed sources evidence. Caveats: Membership rationale cites article IDs and, but their article content is not provided here for citation. Evidence recent evidence review shows 0 kept rows. This entity may overlap with GalaxEye Space Solutions Private Ltd, but the output contract requires scoring both separately. |
| 151 | GalaxEye Space Solutions Private Ltd lowweak | Opp 1 Risk 2 | Thesis: Risk is mainly evidence uncertainty rather than documented adverse developments, because no direct negative evidence or current operating milestones were available after the recent evidence filter. Why now: There is no within the recent evidence window evidence available for this entity in the reviewed sources; recency of any business progress is uncertain. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff for this entity. Membership rationale references article IDs, and: but no article summaries or direct evidence are included in these reviewed sources for citation-level use. Scores are constrained by absence of directional evidence, not by a proven negative business outcome. |
| 152 | GalaxySpace lowweak | Opp 3 Risk 2 | Thesis: No material adverse evidence is present, but the evidence is too limited and research-oriented to reduce uncertainty materially. Why now: The reviewed sources references article: for the research institute setup, yet does not provide the article or direct event details to assess timing or commercial conversion. Caveats: Only one article is considered and no representative article object is provided. Research institute formation is weaker than product, contract, or financing milestones. Commercial impact timing is unclear. |
| 153 | GALVANY lowweak | Opp 2 Risk 2 | Thesis: The same evidence creates moderate execution/classification risk: the company may have financing momentum, but the reviewed sources does not establish that it fits the target cohort or that the funding translates into durable business opportunity. No direct adverse event is available. Why now: The only possible timing angle is the referenced seed raise in the membership rationale, but no -backed available evidence remains after the recent evidence filter, so recency and impact cannot be validated for scoring. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Funding context does not prove target-cohort fit. |
| 154 | Gate Space lowweak | Opp 3 Risk 2 | Thesis: Risk is modest because the evidence base is only one undated, supporting article context with no direct company events beyond funding context, making current status and durability uncertain Why now: For a 1 year+ horizon, funding can matter, but recency is uncertain because the article is explicitly undated and the reviewed sources say undated external evidence is relevance context rather than recency proof Evidence
Caveats: The evidence is weak context and supporting article context, not direct structured company event/fact evidence. The article is undated; the reviewed sources explicitly says recency-sensitive claims should be treated cautiously. Same-article repeated rows are not independent confirmation. |
| 155 | General Atomics mediummedium | Opp 6 Risk 2 | Thesis: The main risk is evidentiary rather than operational: the reviewed sources contain no direct negative evidence, but also no company-specific contract value, backlog, execution milestone, or follow-on detail. The Andromeda item is supporting article context and same-article repeats are not independent confirmation, so the opportunity could be overstated if General Atomics' role is small or non-recurring., April 8, 2026 Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026 Evidence
Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation. |
| 156 | GEOST lowweak | Opp 2 Risk 2 | Thesis: The main risk is lack of current standalone visibility: because evidence appears tied to acquired-business context and no retained rows are included, current operating status, ownership implications, and commercial significance cannot be established from these reviewed sources. Why now: There is no retained within the recent evidence window evidence. Any thesis would rely on older context referenced in the membership rationale, which is insufficient for a stronger rank. Caveats: Reviewed evidence references acquired-business context rather than current standalone operations. No representative articles or retained evidence are included. Low scores reflect missing timely evidence, not a directional call on the business. |
| 157 | GHGSat lowweak | Opp 2 Risk 2 | Thesis: Risk appears limited based on the reviewed sources only because there is no adverse evidence, but confidence is low since there is also no direct traction, contract, funding, or milestone evidence available. Why now: The reviewed sources offers no recent evidence window-supported event timing for a why-now view. Caveats: The membership rationale says GHGSat is the world's leading commercial greenhouse gas monitoring satellite company, but the supporting article content is not available here for ranking use. Absence of negative evidence is not positive evidence. |
| 158 | Globalstar lowweak | Opp 2 Risk 2 | Thesis: There is no direct adverse evidence in the reviewed sources; risk is limited to uncertainty from missing current evidence rather than any documented deterioration. Why now: No within the recent evidence window evidence were available for Globalstar in these reviewed sources, so there is no current catalyst basis to elevate either opportunity or risk. Caveats: Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. Membership rationale cites article IDs, and: but those article contents are not provided here for direct factual citation. Public company status does not improve ranking without directional evidence. |
| 159 | Guodian Gaoke lowweak | Opp 5 Risk 2 | Thesis: No direct negative evidence is shown; key risk is uncertainty around monetization, expansion beyond Phase I, and lack of corroborating direct evidence in the reviewed sources. Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence. Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion. |
| 160 | Guoxing Aerospace Technology lowweak | Opp 2 Risk 2 | Thesis: The reviewed sources also says the company-specific operating category is not clearly established from the provided evidence alone. That uncertainty, plus the lack of retained direct evidence, limits confidence in any positive thesis. Why now: Space-based AI computing could be strategically relevant over 1 year+, but the reviewed sources provide no retained dated evidence to confirm partnership scope, timing, or commercial milestones. Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Partnership mention alone is insufficient to prove durable company impact. |